All translations

Enter a message name below to show all available translations.

Found 2 translations.

Name	Current message text
^h English (en)	==== Iron supplementation ==== A Cochrane review of controlled trials comparing [[Intravenous iron infusion\|intravenous (IV) iron therapy]] with [[Iron supplement\|oral iron]] supplements, found low-certainty evidence that people receiving IV-iron treatment were 1.71 times as likely to reach their target [[hemoglobin]] levels. Overall, hemoglobin was 0.71g/dl higher than those treated with oral iron supplements. Iron stores in the liver, estimated by serum [[ferritin]], were also 224.84 µg/L higher in those receiving IV-iron. However, there was also low-certainty evidence that allergic reactions were more likely following IV-iron therapy. It was unclear whether type of iron therapy administration affects the risk of death from any cause, including cardiovascular, nor whether it may alter the number of people who may require a blood transfusion or dialysis.
^h Japanese (ja)	==== 鉄分補給==== [[Intravenous iron infusion/ja\|静脈内(IV)鉄療法]]と[[Iron supplement/ja\|経口鉄]]サプリメントを比較した対照試験のコクランレビューによると、鉄点滴治療を受けた人が目標[[hemoglobin/ja\|ヘモグロビン]]値に達する可能性は1.71倍であったという確実性の低いエビデンスが得られた。全体として、ヘモグロビンは経口鉄サプリメントによる治療を受けた人よりも0.71g/dl高かった。血清[[ferritin/ja\|フェリチン]]によって推定される肝臓の鉄貯蔵量も、静脈内鉄剤を投与された人の方が224.84 μg/L高かった。しかしながら、鉄の静脈内投与ではアレルギー反応が起こりやすいという確実性の低い証拠もあった。鉄剤投与の種類が心血管系を含むあらゆる原因による死亡リスクに影響するかどうか、また輸血や透析を必要とする人の数が変わるかどうかは不明であった。